Find Your Finish to Anti-Estrogen Therapy
The Breast Cancer Index® (BCI™) Test provides personalized information that empowers you and your oncology care team to make optimal decisions regarding the length of your anti-estrogen treatment. When you can see the finish line, every day feels worth it.
About the Test
The BCI Test provides two results to help you make a personalized decision about the length of your anti-estrogen therapy:
- A clear ‘yes’ or ‘no’ answer to whether an additional five years of anti-estrogen therapy is likely to reduce your risk of recurrence.
- Your individual percent risk of metastatic recurrence after the five year mark, if you take five years of anti-estrogen therapy versus ten.
The BCI Test is the only genomic test recognized by leading oncology guidelines to predict which patients are likely to benefit from continuing anti-estrogen therapy after the first five years of treatment.1,2
The Breast Cancer Index Test is Changing Care—For Good
The BCI Test impacts decisions, helping you determine the right length of anti-estrogen treatment. No more, no less. Following the BCI Test results:
of patients changed their preference either to continue or not continue their anti-estrogen therapy.3
of patients felt more comfortable with their decision.3
Healthcare providers changed anti-estrogen therapy recommendations for 40% of patients, either helping avoid unnecessary side effects or reducing the risk of a potential metastatic recurrence.3
Whether you are likely to benefit or not, the BCI Test gives you and your doctor the information you need to make a personalized decision for you.
“I finally feel like I’m done with cancer treatment.”
Women like Michelle found their finish to anti-estrogen therapy. Let stories like hers help you find yours.
Women like Michelle found their finish to anti-estrogen therapy. Let stories like hers help you find yours.
* Michelle is a patient ambassador for the Breast Cancer Index Test. Statements reflect the speakers' own personal views and interpretations.
References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.5.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed October 28, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 2. Andre F, et al. J Clin Oncol. 2022;40(16):1816-1837. Referenced with permission from the American Society of Clinical Oncology (ASCO®) Clinical Practice Guideline Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer. © American Society of Clinical Oncology. 2025. All rights reserved. To view the most recent and complete version of the guideline, go online to https://ascopubs.org/jco/special/guidelines [ascopubs.org]. ASCO makes no warranties of any kind whatsoever regarding their content, use of application and disclaims any responsibility for their application or use in any way. 3. Sanft TB, et al. J Natl Compr Canc Netw. 2025; 22(2):99-107.